Wednesday, October 4, 2023
Clinical Advances in
Read Overview
Supported by an independent educational grant from Novo Nordisk A/S
Rapid Fire
The obesity challenge
Rapid Fire
What do you know about obesity care?
New Challenge
New Challenge
Steering Committee Chair
Professor of Medicine
Institute of Cardiovascular and Metabolic Medicine
University of Liverpool
Liverpool, UK
Professor
Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Chicago, IL
Professor of Metabolic Medicine
University College Dublin
Dublin, Ireland
National SCOPE Fellow
Obesity Doctor and Senior Bariatric Physician
St George Private Hospital
Kogarah, Sydney, Australia
Professor Emeritus of Medicine
University of Alberta
Edmonton, Canada/Berlin, Germany
Adjunct Professor and Internal Medicine Specialist
McMaster University
York University Medical Director
Diplomate of the American Board of Obesity Medicine
Wharton Medical Clinic
Weight & Diabetes Management
Hamilton Health Sciences
Hamilton, Ontario, Canada
Steering Committee Chair
John Wilding, DM, FRCP, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Mundipharma; Napp Pharmaceuticals Limited; Novo Nordisk; Rhythm Pharmaceuticals; Sanofi; Saniona; Shionogi & Co., Ltd.; Tern; Ysopia
Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Mundipharma; Napp Pharmaceuticals Limited; Novo Nordisk; Rhythm Pharmaceuticals; Sanofi; Saniona; Shionogi & Co., Ltd.; Tern; Ysopia
Research funding from: AstraZeneca; Novo Nordisk
Contracted researcher for: Eli Lilly and Company; Novo Nordisk; Rhythm Pharmaceuticals
Robert Kushner, MD, MS, has the following relevant financial relationships:
Consultant or advisor for: Altimmune; Lilly; Novo Nordisk; Pfizer, Inc.; WW International
Research funding from: Epitomee (former)
Carel Le Roux, PhD, MSc, MBChB, FRCP, FRCPath, has the following relevant financial relationships:
Consultant or advisor for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; GI Dynamics, Inc.; Herbalife; Johnson & Johnson; Keyron; Medtronic, Inc.; Novo Nordisk
Speaker or member of speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; GI Dynamics, Inc.; Herbalife; Johnson & Johnson; Keyron; Medtronic, Inc.; Novo Nordisk
Contracted researcher for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Herbalife; Novo Nordisk
Georgia Rigas, MD, MBBS, FRACG, has the following relevant financial relationships:
Consultant or advisor for: Eli Lilly and Company; Gila Therapeutics, Inc.; iNova Pharmaceuticals; Johnson & Johnson; Nestle HealthScience; Novo Nordisk Pharmaceuticals; Reshape HealthSciences
Speaker or member of speakers bureau for: Aspire; iNova Pharmaceuticals; Johnson & Johnson; Merck Sharp & Dohme; Novo Nordisk Pharmaceuticals; W.L. Gore & Associates
Arya M. Sharma, MD, has the following relevant financial relationships:
Consultant or advisor for: Allurion; Aviva; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Johnson & Johnson; Novo Nordisk; Xeno Biosciences
Speaker or member of speakers bureau for: Johnson & Johnson; Novo Nordisk
Sean Wharton, MD, PharmD, FRCP(C), has the following relevant financial relationship:
Consultant or advisor for: Bausch Health Canada; BioHaven Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk
Speaker or member of speakers bureau for: Bausch Health Canada; BioHaven Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk
Research funding from: Bausch Health Canada; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk